Durie Tangri LLP

IAM Research

The Patent 1000 focuses exclusively on patent practice and has firmly established itself as the definitive 'go-to' resource for those seeking world-class legal patent expertise.

Silver - Firms: litigation

There’s no question about Durie Tangri’s consummate ability to strategise, fight and win bet-the-farm patent litigations: constantly in the thick of the action for Silicon Valley’s high-technology and pharmaceutical players, its lawyers have honed their trial skills to the sharpest point – and none more so than leader Daralyn Durie. “As good as it gets”, she is an “even-keeled, well-organised lawyer who can roll with the changes while remaining focused and on top of everything”. In a patent infringement suit that will shape the market for targeted therapies to treat metastatic melanoma, she is currently representing Berkeley-based Plexxikon against Novartis – a good example of the industry-impactful matters that she routinely takes on. She has also represented Genentech and City of Hope in disputes with various companies seeking to market biosimilar versions of Avastin and Herceptin, Genentech’s blockbuster oncology drugs. At the forefront of the practice – and the market – alongside Durie is Mark Lemley, whose appellate expertise cannot be bested. He recently represented the plaintiffs in Staley v Gilead Sciences, Inc, a dispute which has raised uniquely complex issues at the intersection of antitrust and patent law whose resolution will potentially change the law regarding generic suppression in the pharmaceutical industry. Durie and Lemley couldn’t take such mandates on without great support, and they have it in spades from a cadre of up-and-coming stars including Adam Brausa, Kira Davis (a new addition from Paul Weiss), Tim Saulsbury and Eugene Novikov.

Get unlimited access to all IAM content